The study is designed to assess the safety and tolerability of a novel food ingredient produced from rape seeds supplied as a snack-bar in a 4-week controlled intervention.

An 4-week randomized, double-blind, controlled, parallel-group intervention for assessment of safety and tolerability of a novel rape seed ingredient (RI) followed by a 2-week follow-up period. Baseline measures for digestive symptom frequency questionnaire (DSFQ), blood safety tests and body mass index (BMI) will be collected at screening visit. At the randomization visit, participants' eligibility will be confirmed, and they will be randomly allocated into 2 parallel groups consuming either 20 g (test group) or 0 g (control group) of RI within 2 daily snack bars. During the intervention and follow-up periods participants will bi-weekly respond to a GI symptom questionnaire including DSFQ, stool frequency and stool consistency, and palatability items. At the end of the intervention period (week 4) a clinic visit including BMI and AE recording and blood safety tests will be held.

Inclusion Criteria:

• Signed written informed consent
• Age 18-75 years (inclusive)
• Body mass index (BMI) 18.5 - 30 (inclusive)
• Good general health according to medical history and current health status

Exclusion Criteria:

• Allergy or sensitivity to any ingredient of the study products
• Nut or mustard allergy
• Any major diseases or malfunctions including i. Inflammatory bowel disease or functional bowel disorder or any major gastrointestinal medical condition ii. type 1 or 2 diabetes requiring medication iii. active hepatic, kidney or thyroid disease or disorder except if subject on thyroid replacement therapy iv. myocardial infarction, unstable symptomatic angina pectoris, or transient ischemic attack or stroke within 3 months prior to screening v. cancer or cancer treatment within 5 years prior to screening (not including basal cell carcinoma)
• Medication used for treatment of elevated blood glucose levels
• Pregnancy, lactation or planned pregnancy during the trial
• Clinically significant abnormalities in safety laboratory values according to the investigator
• Strict low-carbohydrate or low-fat diet
• Participation in another clinical trial in the preceding 1 month
• Likelihood of any health or safety risk according to the Investigator
• Likelihood of non-compliance according to the Investigator

double-blind